BioLineRx Ltd. (TLV:BLRX)

BioLineRx Statistics

Total Valuation

BioLineRx has a market cap or net worth of ILS 41.94 million. The enterprise value is 28.92 million.

Market Cap	41.94M
Enterprise Value	28.92M

Important Dates

The last earnings date was Wednesday, May 27, 2026.

Earnings Date	May 27, 2026
Ex-Dividend Date	n/a

Share Statistics

BioLineRx has 2.62 billion shares outstanding. The number of shares has increased by 73.94% in one year.

Current Share Class	2.62B
Shares Outstanding	2.62B
Shares Change (YoY)	+73.94%
Shares Change (QoQ)	-0.08%
Owned by Insiders (%)	0.39%
Owned by Institutions (%)	3.31%
Float	2.51B

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	9.47
PB Ratio	0.64
P/TBV Ratio	40.87
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-1.16
EV / Sales	6.53
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-1.18

Financial Position

The company has a current ratio of 1.58, with a Debt / Equity ratio of 0.44.

Current Ratio	1.58
Quick Ratio	1.41
Debt / Equity	0.44
Debt / EBITDA	n/a
Debt / FCF	-1.16
Interest Coverage	-10.08

Financial Efficiency

Return on equity (ROE) is -46.72% and return on invested capital (ROIC) is -21.12%.

Return on Equity (ROE)	-46.72%
Return on Assets (ROA)	-16.55%
Return on Invested Capital (ROIC)	-21.12%
Return on Capital Employed (ROCE)	-43.30%
Weighted Average Cost of Capital (WACC)	8.27%
Revenue Per Employee	201,206
Profits Per Employee	-1.13M
Employee Count	24
Asset Turnover	0.03
Inventory Turnover	0.11

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -27.27% in the last 52 weeks. The beta is 0.59, so BioLineRx's price volatility has been lower than the market average.

Beta (5Y)	0.59
52-Week Price Change	-27.27%
50-Day Moving Average	1.40
200-Day Moving Average	1.72
Relative Strength Index (RSI)	56.93
Average Volume (20 Days)	9,625,474

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, BioLineRx had revenue of ILS 4.43 million and -24.95 million in losses. Loss per share was -0.01.

Revenue	4.43M
Gross Profit	3.51M
Operating Income	-34.41M
Pretax Income	-30.76M
Net Income	-24.95M
EBITDA	-33.94M
EBIT	-34.41M
Loss Per Share	-0.01

Balance Sheet

The company has 54.79 million in cash and 28.64 million in debt, with a net cash position of 26.15 million or 0.01 per share.

Cash & Cash Equivalents	54.79M
Total Debt	28.64M
Net Cash	26.15M
Net Cash Per Share	0.01
Equity (Book Value)	65.78M
Book Value Per Share	0.02
Working Capital	25.13M

Cash Flow

In the last 12 months, operating cash flow was -24.51 million and capital expenditures -97,876, giving a free cash flow of -24.61 million.

Operating Cash Flow	-24.51M
Capital Expenditures	-97,876
Depreciation & Amortization	431,314
Net Borrowing	-14.21M
Free Cash Flow	-24.61M
FCF Per Share	-0.01

Margins

Gross Margin	79.24%
Operating Margin	-777.46%
Pretax Margin	-694.79%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

BioLineRx does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-73.94%
Shareholder Yield	-73.94%
Earnings Yield	-59.50%
FCF Yield	-58.68%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on June 7, 2015. It was a reverse split with a ratio of 0.1.

Last Split Date	Jun 7, 2015
Split Type	Reverse
Split Ratio	0.1

Scores

BioLineRx has an Altman Z-Score of -14.68 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-14.68
Piotroski F-Score	3